Skip to main content
Top
Published in: Rheumatology International 9/2011

01-09-2011 | Case Report

Bowel perforations in a patient affected by Churg–Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery?

Authors: Dario Venditti, Balassone Valerio, Benedetto Ielpo, Oreste Buonomo, Giuseppe Petrella

Published in: Rheumatology International | Issue 9/2011

Login to get access

Abstract

Churg–Strauss syndrome is a relapsing–remitting vasculitis that frequently involves digestive system. Ischemic perforation of the large bowel is relatively rare and potentially life threatening. We report a case treated with high dose of steroids for a relapsing of Churg–Strauss vasculopathy that underwent emergency surgery for multiple large-bowel perforations. Massive use of steroids is common for controlling relapse of this disease, but this increases the risk of intestinal perforation. A prompt switching to alternative drugs when intestinal tract is involved should be considered in order to prevent surgery.
Literature
1.
go back to reference Abril A, Calamia KT, Cohen MD (2003) The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 33:106–114PubMedCrossRef Abril A, Calamia KT, Cohen MD (2003) The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 33:106–114PubMedCrossRef
2.
go back to reference Masi AT, Hunder GG, Lie JT (1990) The American College of Rheumatology criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–1100PubMedCrossRef Masi AT, Hunder GG, Lie JT (1990) The American College of Rheumatology criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–1100PubMedCrossRef
3.
go back to reference Guillevin L, Lhote F, Gauraud M, Cohen P, Jarrousse B, Lortholary O et al (1996) Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. Medicine 75:17–28PubMedCrossRef Guillevin L, Lhote F, Gauraud M, Cohen P, Jarrousse B, Lortholary O et al (1996) Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. Medicine 75:17–28PubMedCrossRef
4.
go back to reference Kim YB, Choi SW, Park IS, Han JY, Hur YS, Chu YC (2000) Churg–Strauss syndrome with perforating ulcers of the colon. J Korean Med Sci 15(5):585–588PubMed Kim YB, Choi SW, Park IS, Han JY, Hur YS, Chu YC (2000) Churg–Strauss syndrome with perforating ulcers of the colon. J Korean Med Sci 15(5):585–588PubMed
5.
go back to reference Murakami S et al (2004) Churg–Strauss syndrome manifesting as perforation of the small intestine: report of a case. Surg Today 34:788–792PubMed Murakami S et al (2004) Churg–Strauss syndrome manifesting as perforation of the small intestine: report of a case. Surg Today 34:788–792PubMed
6.
go back to reference Mémain N, De Bandt M, Guillevin L, Wechsler B, Meyer O (2002) Delayed relapse of Churg–Strauss syndrome manifesting as colon ulcers with mucosal granulomas: 3 cases. J Rheumatol 29(2):388–391PubMed Mémain N, De Bandt M, Guillevin L, Wechsler B, Meyer O (2002) Delayed relapse of Churg–Strauss syndrome manifesting as colon ulcers with mucosal granulomas: 3 cases. J Rheumatol 29(2):388–391PubMed
7.
8.
go back to reference Pepper RJ, Fabre MA, Pavesio C et al (2008) Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47:1104–1105PubMedCrossRef Pepper RJ, Fabre MA, Pavesio C et al (2008) Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47:1104–1105PubMedCrossRef
Metadata
Title
Bowel perforations in a patient affected by Churg–Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery?
Authors
Dario Venditti
Balassone Valerio
Benedetto Ielpo
Oreste Buonomo
Giuseppe Petrella
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1289-5

Other articles of this Issue 9/2011

Rheumatology International 9/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine